Biotech

Biotech

After nearly dying five times, a young doctor learned to treat himself. Now he wants to help others with rare disease

By Matthew Herper

Biotech

Biotech veteran Tony Coles to become CEO of Pfizer neuroscience spinout Cerevel

By Matthew Herper

Biotech

Lung cancer drug Lilly bought for $8 billion delivers strong results

By Matthew Herper

Biotech

Data on Amgen’s KRAS-blocking cancer drug are encouraging, but also raise new questions

By Adam Feuerstein

Pharmalot

Judge dismisses real estate tycoon’s lawsuit against his son

By Jonathan Saltzman — Boston Globe

Adam's Take

Biotech’s ‘distracted boyfriend’ is $3 billion richer. His fellow investors are still waiting for their share

By Adam Feuerstein

The Readout LOUD

Listen: Pharma existentialism, mainstreaming cyborgs, & FDA palace intrigue

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Biotech

How drugs got on TV, uBiome’s last days, & and the (possible) biotech future of an ex-Goldman exec

By Damian Garde

Biotech

Did a biotech exec crib a New Yorker cartoon?

By Jonathan Saltzman — Boston Globe

Business

Watch: Direct-to-consumer drug advertising, explained

By Damian Garde

Biotech

7 things to know about Aimmune’s peanut allergy therapy ahead of a pivotal FDA meeting

By Adam Feuerstein

Biotech

Vertex’s next act: a billion-dollar bet on a cure for type 1 diabetes

By Damian Garde

Biotech

New Sanofi CEO wants to tap digital technology to improve drug research and sales

By Matthew Herper

Special Report

Chinese scientists came to the U.S. to pursue their dreams. Under tighter scrutiny, many are returning home

By Diana Cai

Biotech

‘I propose that we grow up a little bit’: Biohackers grapple with when to reject mainstream science — and when to embrace it

By Rebecca Robbins

Biotech

Executive draws on his career experience (literally)

By Jonathan Saltzman — Boston Globe

The Readout LOUD

Listen: Purdue, J&J, and a week of big opioid crisis news

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Biotech

Biotech industry aims to spark girls’ interests in science long before high school

By Isabella Tran — Boston Globe

Biotech

Vertex sinks on reports of deaths of patients taking cystic fibrosis drug

By Damian Garde

Adam's Take

Mark Schoenebaum was the best biotech analyst ever. Better still, he was a great person

By Adam Feuerstein

Biotech

Celgene sells psoriasis pill to Amgen for $13.4 billion, clearing way for close of Bristol merger

By Adam Feuerstein

The Readout LOUD

Listen: Sarepta keeps a secret, an online army mobilizes, & China embraces biotech

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Biotech

FDA on Novartis data manipulation controversy: ‘We happened to be lucky’

By Matthew Herper

Adam's Take

FDA’s Sarepta rejection is rooted in the past, and will weigh on its future

By Adam Feuerstein

Biotech

Top scientist categorically denies any wrongdoing in Novartis data manipulation scandal

By Matthew Herper

An FDA advisory panel is reviewing Aimmune’s peanut allergy therapy. Here’s what’s happening

A consultant is suing Nocion Therapeutics for allegedly promising him the CEO job — and then passing him over

Listen: Pelosi’s drug pricing plan, Moderna’s mRNA drug factories, and a DIY disease cure

With some safety caveats, new Moderna data show mRNA can teach the body to make its own medicine

After nearly dying five times, a young doctor learned to treat himself. Now he wants to help others with rare disease

Biotech veteran Tony Coles to become CEO of Pfizer neuroscience spinout Cerevel

Lung cancer drug Lilly bought for $8 billion delivers strong results

Data on Amgen’s KRAS-blocking cancer drug are encouraging, but also raise new questions

Judge dismisses real estate tycoon’s lawsuit against his son

Biotech’s ‘distracted boyfriend’ is $3 billion richer. His fellow investors are still waiting for their share

Listen: Pharma existentialism, mainstreaming cyborgs, & FDA palace intrigue

How drugs got on TV, uBiome’s last days, & and the (possible) biotech future of an ex-Goldman exec

Did a biotech exec crib a New Yorker cartoon?

Watch: Direct-to-consumer drug advertising, explained

7 things to know about Aimmune’s peanut allergy therapy ahead of a pivotal FDA meeting

Vertex’s next act: a billion-dollar bet on a cure for type 1 diabetes

New Sanofi CEO wants to tap digital technology to improve drug research and sales

Chinese scientists came to the U.S. to pursue their dreams. Under tighter scrutiny, many are returning home

‘I propose that we grow up a little bit’: Biohackers grapple with when to reject mainstream science — and when to embrace it

Executive draws on his career experience (literally)

Listen: Purdue, J&J, and a week of big opioid crisis news

Biotech industry aims to spark girls’ interests in science long before high school

Vertex sinks on reports of deaths of patients taking cystic fibrosis drug

Mark Schoenebaum was the best biotech analyst ever. Better still, he was a great person

Celgene sells psoriasis pill to Amgen for $13.4 billion, clearing way for close of Bristol merger

Listen: Sarepta keeps a secret, an online army mobilizes, & China embraces biotech

FDA on Novartis data manipulation controversy: ‘We happened to be lucky’

FDA’s Sarepta rejection is rooted in the past, and will weigh on its future

Top scientist categorically denies any wrongdoing in Novartis data manipulation scandal